KAYTUS
23.5.2024 17:14:31 CEST | Business Wire | Press release
KAYTUS, a leading IT infrastructure provider, unveiled the KR2280V2 2U, 2-socket flagship server at ISC High Performance 2024. This powerhouse server supports the 4th/5th Gen Intel® Xeon®, 4th Gen AMD EPYCTM, and AmpereOne® processors, offering an impressive array of storage combinations with up to 20 LFF drives, 45 SFF drives, or 24 E3.S SSDs. When upgraded with CXL modules, the KR2280V2 horizontally expands to 16 DIMMs, effortlessly meeting the demands of memory-intensive applications. Its innovative front I/O configuration delivers remarkable scalability, supporting up to 20 PCIe 5.0 devices, setting a new benchmark in performance. With its flexible compute capabilities and adaptable storage and I/O designs, the KR2280V2 is engineered to accommodate a wide spectrum of business needs— ranging from general computing to accelerated computing, and from massive storage capacity to high-performance I/O-oriented applications. This versatility makes it the ultimate solution for diverse application scenarios, ensuring consistent and efficient operation and maintenance.
Revolutionizing Diverse Applications Scenarios with Versatile Compute Power
To deliver the best computing solutions for diverse scenarios, the IT architecture of data centers is rapidly evolving and becoming increasingly sophisticated. As business needs diversify, a single chip can no longer meet the demands of complex, high-efficiency computing, leading to the emergence of various acceleration chips. This rapid evolution places new demands on processors' energy efficiency and core performance. The KR2280V2 boldly rises to this challenge by supporting three major computing platforms: Intel® Xeon®, AMD EPYC™, and AmpereOne®. This versatility offers a wide range of computing power options, perfectly tailored for different scenarios. By unifying management interfaces, the KR2280V2 dramatically reduces operation and maintenance pressure in heterogeneous computing configurations, making it exceptionally user-friendly and efficient.
Unparalleled Configuration Flexibility Optimized for Peak Application Performance
Through highly advanced modularization, KR2280V2 enables dynamic configurations of storage, I/O, and acceleration modules, offering an impressive array of over 100 configurations. This versatility seamlessly adapts to various scenarios, from general computing to cutting-edge heterogeneous computing, from storage-intensive to blazing-fast I/O-intensive applications, and from traditional rear I/O maintenance to innovative front I/O maintenance design. When it comes to energy efficiency, the KR2280V2 leads the way with its fully compatible cold-plated liquid cooling design, enhanced with state-of-the-art leakage detection mechanisms and bolstered system reliability.
Industry's First to Achieve BSI Cryptographic Uncompromising Security Encryption
The cryptographic module employed in KR2280V2's BMC out-of-band management module establishes a new security benchmark. It adheres fully to the stringent ISO/IEC 19790:2012 requirements, delivering excellence across role permissions, service and authentication, software/firmware security, operating environment security, and full-process self-inspection. Simultaneously, it ensures an end-to-end security system through the integration of state-of-the-art technologies. From dual flash chips to BMC self-recovery mechanisms, comprehensive access control, and multiple authentications, every aspect is meticulously designed to safeguard critical business data with uncompromising encryption. The KR2280V2 sets the standard for data security in the digital age.
About KAYTUS
KAYTUS is a leading provider of IT infrastructure solutions, delivering a diverse range of cutting-edge, open, and eco-friendly products for cloud, AI, edge computing, and other emerging applications. With a customer-centric approach, KAYTUS is agile and responsive to user needs through its adaptable business model. Discover more at KAYTUS.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240523414563/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
